Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

2.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surveillance for Candida auris - United States, 2022-2024.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2026
Same author

Seasonal Analysis of Candida auris Detection Rates at 80 Wastewater Monitoring Sites in the United States, December 2023-November 2024.

Environmental microbiology reports·2026
Same author

Children Present or Witnessing Violent Deaths and Suicides.

JAMA pediatrics·2026
Same author

Updated Genomic Epidemiologic Description of Candida (Candidozyma) auris, United States.

Emerging infectious diseases·2026
Same author

Yeast identification, antifungal susceptibility testing, and <i>Candida auris</i> screening practices at acute care hospitals and long-term acute care hospitals, United States.

Journal of clinical microbiology·2026
Same author

Candida glabrata emerges as the most common cause of candidemia: analysis of a large hospital-based database, United States, 2016-2024.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jun 29, 2025

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

13.8K

Candida auris in US Correctional Facilities.

Ian Hennessee, Kaitlin Forsberg, Jalysa Erskine

    Emerging Infectious Diseases
    |April 1, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Candida auris (C. auris) infections in correctional facilities are rare but can occur in incarcerated individuals. Facilities face challenges in managing C. auris cases and preventing its spread.

    Keywords:
    Candida aurisUnited Statesantimicrobial resistancecorrectional facilitiescorrectional healthfungiinfection prevention and controlmultidrug-resistant organismprisons

    More Related Videos

    Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging
    03:24

    Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging

    Published on: March 22, 2024

    1.5K
    Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening
    08:05

    Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening

    Published on: July 18, 2012

    13.7K

    Related Experiment Videos

    Last Updated: Jun 29, 2025

    Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
    08:45

    Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

    Published on: December 28, 2017

    13.8K
    Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging
    03:24

    Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging

    Published on: March 22, 2024

    1.5K
    Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening
    08:05

    Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening

    Published on: July 18, 2012

    13.7K

    Area of Science:

    • Infectious Diseases
    • Public Health
    • Mycology

    Background:

    • Candida auris (C. auris) is an emerging, multidrug-resistant fungal pathogen.
    • C. auris primarily affects patients in healthcare settings.
    • Limited data exist on C. auris in correctional facilities.

    Purpose of the Study:

    • To describe cases of C. auris in incarcerated patients.
    • To identify challenges in managing C. auris within correctional facilities.
    • To inform public health recommendations for C. auris prevention in this setting.

    Main Methods:

    • Retrospective case series of 13 patients transferred to correctional facilities with positive C. auris specimens.
    • Analysis of challenges reported by correctional facilities regarding patient management and infection control.
    • Review of patient data from January 2020 to December 2022.

    Main Results:

    • Thirteen patients with C. auris were identified in correctional facilities.
    • Facilities reported significant challenges in patient management and implementing C. auris prevention measures.
    • Challenges differed based on patient housing (medical vs. general population units).

    Conclusions:

    • Candida auris cases can occur in incarcerated populations, especially those with risk factors.
    • Correctional facilities require tailored strategies to manage C. auris and prevent transmission.
    • Addressing setting-specific challenges is crucial for effective C. auris control in prisons.